产品介绍：
产品说明
一般描述
Zibotentan is an orally bioavailable, non-peptide ETA (endothelin) receptor-specific antagonist, with no activity against ETB receptor.
包装
5, 25 mg in glass bottle
生化/生理作用
Zibotentan has been found to inhibit cell proliferation, invasion and metastasis in cancer models. In clinical trials on patients with castration-resistant prostate cancer and bone metastasis, who were pain-free or had mild pain, zibotentan treatment resulted in better overall survival as compared to placebo.
Zibotentan is a potent and selective endothelin ET(A) receptor antagonist with an IC50 of 21 nM for the ETA receptor subtype and no binding observed even at 10,000 nM for ETB.
基本信息
| 经验(实验)分子式 | C19H16N6O4S |
| 分子量 | 424.43 |
| MDL编号 | MFCD09955343 |
| PubChem化学物质编号 | 329825958 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| 颜色 | white to beige |
| 溶解性 | DMSO: 5 mg/mL, clear (warmed) |
| 储存温度 | −20℃ |
| SMILES string | O=S(C1=C(C2=CC=C(C3=NN=CO3)C=C2)N=CC=C1)(NC4=NC=C(C)N=C4OC)=O |
| InChI | 1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25) |
| InChI key | FJHHZXWJVIEFGJ-UHFFFAOYSA-N |
| Gene Information | human ... EDNRA(1909) |
安全信息
| 象形图 |  |
| 警示用语： | Warning |
| 危险声明 | H302 |
| 预防措施声明 | P301 + P312 + P330 |
| 危险分类 | Acute Tox. 4 Oral |
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
